27 February 2007 Pharmacokinetic study of a systemically administered novel liposomal Temoporfin formulation in an animal tumor model
Author Affiliations +
Abstract
Meso-tetra(hydroxyphenyl)chlorin (mTHPC)(international generic name Temoporfin) is a potent photosensitizer used for photodynamic therapy (PDT). In this study the pharmacokinetics of a systemically administered novel lipid formulation of Temoporfin in a murine tumor model has been investigated. Fluorescence spectroscopy measurements were performed at several time intervals following drug administration, yielding information on the Temoporfin concentration within excised internal organs as a function of time after injection. Both point-monitoring and imaging setups were used. The acquired fluorescence data were correlated to the concentration of Temoporfin obtained with High Performance Liquid Chromatography (HPLC). There was a significant correlation between the fluorescence methods and HPLC for most organs investigated. The pharmacokinetics of this new liposomal formulation of Temoporfin exhibited a rather flat temporal profile in the time interval 2-8 hours in this study.
© (2007) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Jenny Svensson, Ann Johansson, Niels Bendsoe, Susanna Gräfe, Tilmann Trebst, Stefan Andersson-Engels, Katarina Svanberg, "Pharmacokinetic study of a systemically administered novel liposomal Temoporfin formulation in an animal tumor model", Proc. SPIE 6427, Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy XVI, 64270T (27 February 2007); doi: 10.1117/12.698932; https://doi.org/10.1117/12.698932
PROCEEDINGS
8 PAGES


SHARE
Back to Top